GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Baijin Life Science Holdings Ltd (OTCPK:MNNGF) » Definitions » Debt-to-Revenue

MNNGF (Baijin Life Science Holdings) Debt-to-Revenue : 0.46 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Baijin Life Science Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Baijin Life Science Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.63 Mil. Baijin Life Science Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6.80 Mil. Baijin Life Science Holdings's annualized Revenue for the quarter that ended in Sep. 2024 was $18.20 Mil. Baijin Life Science Holdings's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.46.


Baijin Life Science Holdings Debt-to-Revenue Historical Data

The historical data trend for Baijin Life Science Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baijin Life Science Holdings Debt-to-Revenue Chart

Baijin Life Science Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.73 0.51 0.03 0.95

Baijin Life Science Holdings Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.07 0.90 0.46

Competitive Comparison of Baijin Life Science Holdings's Debt-to-Revenue

For the Luxury Goods subindustry, Baijin Life Science Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baijin Life Science Holdings's Debt-to-Revenue Distribution in the Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Baijin Life Science Holdings's Debt-to-Revenue falls into.


;
;

Baijin Life Science Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Baijin Life Science Holdings's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.346 + 5.197) / 6.861
=0.95

Baijin Life Science Holdings's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.632 + 6.802) / 18.2
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Sep. 2024) Revenue data.


Baijin Life Science Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Baijin Life Science Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Baijin Life Science Holdings Business Description

Traded in Other Exchanges
Address
66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company produces health products that are affordable for the general public. The business segments of the company are Life Science segment which includes cellular technology-based services, provide including cellular drugs R&D, large molecule drugs R&D, clinical research services and R&D and sales on self-owned skincare brand, and Fine Jewelry segment that focuses on the procurement, processing, design, production and wholesale distribution of pearls and fine jewelry products.

Baijin Life Science Holdings Headlines